Pilot study of the optimal protocol of low dose step-up follicle stimulating hormone therapy for infertile women

Reproductive medicine and biology

article

Toshiya Matsuzaki¹  Takeshi Iwasa¹  Rie Yanagihara¹  Mizuki Komasaka¹  Kiyohito Yano¹  Yiliyasi Mayila¹  Ayaka Tachibana¹  Yuri Yamamoto¹  Takeshi Kato¹  Akira Kuwahara¹  Minoru Irahara¹ 

[1] Department of Obstetrics and Gynecology, Graduate School of Biomedical Sciences, Tokushima University;Student Laboratory, Faculty of Medicine, Tokushima University;Department of Obstetrics and Gynecology, Shikoku-Central Hospital

关键词: low dose FSH;    ovarian stimulation;    ovulation induction;    polycystic ovary syndrome;    WHO group II;   

DOI  :  10.1002/rmb2.12208

学科分类：工业工程学

来源: Wiley

【 摘 要 】

Purpose To evaluate the optimized protocol of low dose follicle-stimulating hormone (FSH) therapy that has a starting dose of 50 IU/62.5 IU with a small increment dose (12.5 IU) for women with World Health Organization (WHO) II ovulatory disorder and unexplained infertility. Methods Anovulatory women with WHO group II ovulatory disorder (ovulation induction [OI] patients, n = 29), and with an unexplained infertility (ovarian stimulation [OS] patients, n = 21) were enrolled. The protocol of low dose step-up FSH therapy was optimized for the starting dose as 50 IU (body mass index [BMI] < 20 group) and 62.5 IU (BMI ≥ 20 group) with the increment dose of 12.5 IU. Study outcomes were ovulation, monofollicular development and other variables. Results In the OIpatients, the ovulation rate was 100% (BMI < 20 group) and 90.9% (BMI ≥ 20 group). Monofollicular development was 80.0% (BMI < 20) and 77.3% (BMI ≥ 20). The pregnancy rate was 60% (3/5 BMI < 20) and 18.2% (4/22 BMI ≥ 20). There was no multiple pregnancy. In the OSpatients, the ovulation rate was 100%. Monofollicular development was 85.7% (BMI < 20) and 76.6% (BMI ≥ 20). No pregnancy was achieved in the OSpatients. Conclusion Optimized protocol of low dose FSH therapy setting a starting dose 50 IU/62.5 IU by BMI with an increment dose of 12.5 IU was safe and highly effective in WHO group II anovulatory patients. However, this protocol seemed uneffective for patients with unexplained infertility.

【 授权许可】

CC BY|CC BY-NC|CC BY-NC-ND